1. Weiner F, Kanter Y, Kol S, Barzilai D. Computer implementation of the new diabetes classification scheme. Meth Inform Med 21:191, 1982. Full text
2. Kanter Y, Kol S, Weiner F. Intravenous glucose tolerance test in gestational diabetes and pregnancy: manual vs. computerized assessment. Eur J Obstet Gynecol Reprod Biol. 27:307, 1988. Full text
3. Barnea ER, Fares F, Kol S. Stimulatory effect of prolactin on human placental progesterone secretion at term in vitro: possible inhibitory effect on estradiol secretion. Placenta 10:37, 1989.
4. Barnea ER, Perlman R, Fakih H, Bick T, Kol S, Hochberg Z. The role of catecholamines in estradiol and progesterone secretion by cultured explants and cells of human term placenta. Acta Endocrinologica 121:767, 1989. Full text
5. Barnea ER, Simon RJ, Kol S, Human embryonal extracts modulate placental function in the first trimester: effect of visceral tissues upon chorionic gonadotropin and progesterone secretion. Placenta 10:331, 1989.
6. Kol S, Gal D, Friedman M, Paldi E. Case report: preoperative diagnosis of fallopian tube carcinoma by TVS and CA-125. Gynecologic Oncology 37:129, 1990. Full text
7. Kol S, Jakobi P, Paldi E. The intrauterine device, a transitional period. Harefua 118:676, 1990.Full text
8. Adir Y, Bitterman H, Kol S, Melamed Y. Hyperbaric oxygen treatment for carbon monoxide intoxication acquired in the sealed room during the Persian Gulf War. Israel Journal of Medical Sciences 27:669, 1991. Full text
9. Barnea ER, Ashkenazy R, Tal Y, Kol S, Sarne Y. Effect of b-endorphin on human chorionic gonadotrophin secretion by placental explants. Hum Reprod 6: 1327, 1991.
10. Jakobi P, Kol S, Weissman A, Krivoy N. Peripartum changes in free and protein bound digoxin like immuno-reactive factor. J Reprod Med 37:127, 1992.
11. Adir Y, Kol S, Melamed Y. Carbon monoxide and coronary artery disease. Harefuah, 122:249, 1992. Full text
12. Nachum Z, Kol S, Adir Y, Melamed Y. Massive air embolism – a possible cause of death after operative hysteroscopy using a 32% dextran 70 pump. Fertil Steril 58:836, 1992. Full text
13. Kol S, Ammar R, Weisz G, Melamed Y. Hyperbaric oxygenation for arterial air embolism during cardiopulmonary bypass. Ann Thorac Surg, 55:401, 1993. Full text
14. Kol S, Weisz G, Melamed Y. Pulmonary barotrauma after a free dive – a possible mechanism. Aviat Space Environ Med 64:236, 1993. Full text
15. Kol S, Levron J, Lewit N, Drugan A, Itskovitz-Eldor J. The natural history of multiple pregnancies after assisted reproduction: Is spontaneous fetal reduction a clinically significant phenomenon? Fertil Steril 60:127, 1993. Full text
16. Kol S, Adir Y, Gordon CR, Melamed Y. Oxy-helium treatment of severe spinal decompression sickness after air diving. Undersea Biomed Res 20:147, 1993. Full text
17. Itskovitz-Eldor J, Levron J, Kol S. Use of GnRH-agonist to cause ovulation and prevent ovarian hyperstimulation sundrome. Clin Obstet Gynecol, 36:701, 1993. Full text
18. Aharon-Peretz J, Adir Y, Gordon CR, Kol S. Gal N, Melamed Y. Spinal Decompression sickness in sport diving. Arch Neurol 50:753, 1993. Full text
19. Kol S, Gordon CR, Melamed Y. The potential role of oxygen in the prevention of neurologic deficit after cardiac surgery. Intensive & Critical Care Digest 12:48, 1993. Full text
20. Payne DW, Shackeleton C, Toms H, Ben-Shlomo I, Kol S, deMoura M, Strauss JF, Adashi EY. A novel nonhepatic hydroxycholosterol 7ahydroxylase that is markedly stimulated by interleukin-1b J Biol Chem 270:18888-96, 1995. Full text
21. Kol S, Thaler I, Paz N, Shmueli O. Interpretation of nonstress tests by an artificial neural network. Am J Obstet Gynecol 172:1372, 1995. Full text
22. Kol S, Ben-Shlomo I, Adashi EY, Rohan RM. Simplified riboprobe purification using starslucent straws as gel tubes. Gen Alalysis 1996;12:129-132. Full text
23. Ben-Shlomo I, Kol S, Ando M, Altman KR, Putowski LT, Rohan RM, Adashi EY Ovarian expression, cellular localization, and hormonal regulation of rat secretory phospholipase A2: increased expression by interleukin-1 and by gonadotropins. Biol Reprod 1997;57:217-225. Full text
24. Scherzer WJ, Putowski LT, Kol S, Adashi EY, Rohan RM. Detection and In Vitro Hormonal Regulation of Rat Ovarian Type I and Type II Interleukin-1 Receptor mRNA: Increased Expression During the Periovulatory Period. J Soc Gyn Invest 1996;3:131-9. Full text
25. Kol S, Ben-Shlomo I, Ruutianen K, Ando M, Resnick CE, Rohan RM, Adashi EY.The midcycle increase in ovarian glucose uptake is associated with enhanced expression of glucose transporter 3. J Clin Invest 1997, 99:2274-2283. Full text
26.Kol S, Ben-Shlomo I, Payne DW, Ando M, Rohan RM, Adashi EY. Glucocorticoids suppress basal (but not interleukin-1-supported) ovarian phospholipase A2 activity: evidence for glucocorticoid receptor-mediated regulation.Mol Cell Endocrinol 137:117-25, 1998. Full text
27. Ben-Shlomo I, Kol S, Roeder LM, Resnick CE, Hurwitz A, Payne DW, Adashi EY. Interleukin (IL)-1b Increases Glucose Uptake and Induces Glycolysis in aerobically Cultured Rat Ovarian Cells: Evidence that IL-1b may Mediate the Gonadotropin-Induced Midcyle Metabolic Shift. Endocrinology 1997;138:2680-2688. Full text
28. Kol S, Ben-Shlomo I, Ando M, Payne DW, Adashi EY. Interleukin-1b Stimulates Ovarian Phospholipase A2 (PLA2) Expression and Activity: Up-regulation of Both Secretory and Cystosolic PLA2. Endocrinology 1997;138: 314-321. Full text
29. Kol S, Ruutiainen K, Ben-Shlomo I, Ando M, Payne DW, Adashi EY. The Rat Ovarian Phospholipase A2 System: Gene Expression, Cellular Localization, Activity Characterization, and Interleukin-1 Dependence. Endocrinology 1997;138:322-331. Full text
30. Kol S, Lewit N, Itskovitz-Eldor J. Ovarian Hyperstimulation Syndrome after using Gonadotropin-releasing Hormone Agonist as a Trigger of Ovulation: Causes and implications. Hum Reprod 11:1143, 1996. Full text
31. Lewit N, Kol S, Itskovitz-Eldor J. Does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome? Fertil Steril 66:654, 1996. Full text
32. Lewit N, Kol S, Manor D, Itskovitz-Eldor J. Comparison of GnRH Analogs And Hcg For The Induction of Ovulation And Preventation of Ovarian Hyperstimulation Syndrome (OHSS): A Case-control Study. Hum Reprod 11:1399, 1996. Full text
33. Lewit N, Kol S, Manor D, Itskovitz-Eldor J. The Use of GnRH Analogues For the Induction of Preovulatory Gonadotropin Surge In Assisted Reproduction and Prevention of Ovarian Hyperstimulation Syndrome. Gynecol Endocrinol 9 (Suppl) 4:13-17, 1995. Full text
34. Lightman A, Kol S, Wayner V, Vertman D, Manor D, Itskovitz-Eldor J. The presence of a sponsoring embryo in a batch of poor quality thawed embryos significantly increases pregnancy and implantation rate. Fertil Steril 67:711-6, 1997. Full text
35. Kol S, Karnieli E, Kraiem Z, Itskovitz-Eldor J, Lightman A, Ish-Shalom S. Thyroid function in early normal pregnancy: transient suppression of thyroid stimulating hormone, and stimulation of triiodothyronine. Gyncol Obstet Invest 42:227-229, 1996. Full text
36. Manor D, Kol S, Lewit N, Lightman A, Stein D, Pillar M, Itskovitz-Eldor J. Undocumented embryos: Do not trash them, FISH them. Hum Reprod 11:2502-2506, 1996. Full text
37. Itskovitz-Eldor J, Filmar S, Manor D, Stein D, Lightman A, Kol S. Assisted implantation: Direct intra-endometrial embryo transfer. Gyncol Obstet Invest 43:73-75, 1997. Full text
38. Kent-First MG, Kol S, Muallem A, Manor D, Blazer S, First N, Itskovitz-Eldor J. The incidence and possible relevance of Y-linked microdeletions in ICSI derived babies and their infertile fathers. Mol Hum Reprod 2:943-950, 1996. Full text
39. Itskovitz-Eldor J, Kol S, Lewit N, Sealey JE. Ovarian origin of plasma and peritoneal fluid prorenin in early pregnancy and in patients with ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 82:461-464, 1997. Full text
40. Shupak A, Melamed Y, Ramon Y, Bentur Y, Abramovich A, Kol S. Helium and oxygen treatment of severe air diving-induced neurologic decompression sickness. Arch Neurol 54:305-311, 1997. Full text
41.Derman SG, Kol S, Ben-Shlomo I, Resnick CE, Rohan RM, Adashi EY. Transforming growth factor-beta1 is a potent inhibitor of interleukin-1beta action in whole ovarian dispersates. J Endocrinol 160:415-423, 1999. Full text
42.Kol S, Ben-Shlomo1 I, Ando M, Adashi1 EY. Insulin-like growth factor I affects the intraovarian interleukin-1 system: evidence for suppression of type I interleukin-1 receptor expression and enhancement of secretory phospholipase A2 expression and activity. Mol Hum Reprod 1997, 3:1095-1099. Full text
43. Ando M, Kol S, Kokia E, Ruutiainen-Altman K, Sirois J, Rohan RM, Payne DW, Adashi EY. Rat ovarian prostaglandin endoperoxide synthase-1 and -2: periovulatory expression of granulosa cell-based interleukin-1-dependent enzymes. Endocrinology 139:2501-8, 1998. Full text
44. Itskovitz-Eldor J, Kol S, Mannaerts B, Coelingh Bennink H. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462). Hum Reprod 13:294-5, 1998. Full text
45. Kol S, Ben-Shlomo I, Ando M, Adashi EY. Insulin-like growth factor I affects the intraovarian interleukin-1 system: evidence for suppression of type I interleukin-1 receptor expression and enhancement of secretory phospholipase A2 expression and activity.Mol Hum Reprod 3:1095-9, 1997. Full text
46. Kol S, Donesky BW, Ruutiainen-Altman K, Ben-Shlomo I, Irahara M, Ando M, Rohan RM, Adashi EY. Ovarian Interleukin-1 Receptor Antagonist in Rats: Gene Expression, Cellular Localization, Cyclic Variation, and Hormonal Regulation of a Potential Determinant of Interleukin-1 Action. Biol Reprod 61:274-282, 1999. Full text
47. Kol S, Ruutiainen-Altman K, Scherzer WJ, Ben-Shlomo I, Ando M, Rohan RM, Adashi EY. The rat intraovarian interleukin (IL)-1 system: cellular localization, cyclic variation and hormonal regulation of IL-1beta and of the type I and type II IL-1 receptors. Mol Cell Endocrinol 149:115-28, 1999. Full text
48. Coffler MS, Kol S, Drugan A, Itskovitz-Eldor J Early transvaginal embryo aspiration: a safer method for selective reduction in high order multiple gestations. Hum Reprod 14:1875-1878, 1999. Full text
49. Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, Mannaerts B, and Itskovitz-Eldor J. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze–thaw cycles . Hum Reprod 14:2242-2244, 1999. Full text
50. Lightman A, Kol S, Itskovitz-Eldor J. A prospective randomized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles. Hum Reprod 14:2596-2599, 1999. Full text
51. Ando M, Kol S, Irahara M, Sirois J, Adashi EY. Non-steroidal anti-inflammatory drugs (NSAIDs) block the late, prostanoid-dependent/ceramide-independent component of ovarian IL-1 action: implications for the ovulatory process. Mol Cell Endocrinol 157:21-30, 1999. Full text
52. Irahara M, Ando M, Kol S, Adashi EY. Expression and hormonal regulation of rat ovarian interleukin-1beta converting enzyme, a putative apoptotic marker: endocrine- and aracrine-dependence. J Reprod Immunol 45:67-79, 1999. Full text
53. Kol S, Wong KH, Ando M, Ben-Shlomo I, Adashi EY. Rat ovarian interleukin-1alpha: interleukin-1-dependent in vitro expression. Endocrine 11:269-75, 1999. Full text
54. Kol S, Itskovitz-Eldor J. Severe OHSS: Yes, there is a strategy to prevent it! Hum Reprod 2000 Webtrack (1.8.2000). Full text
55. Kol S. GnRH antagonists in ART: lower embryo implantation? Hum Reprod; 5:1881-1882, 2000 Webtrack (12.6.2000). Full text
56. Lewit N, Kol S. The low responder female IVF patient with hypogonadotropic hypogonadism: do not give up! Fertil Steril 74:401-2, 2000. Full text
57. Beloosesky R, Kol S Lightman A, Itskovitz-Eldor J. Ovarian stimulation in in vitro fertilization with or without the "long" gonadotropin-releasing hormone agonist protocol: effect on cycle duration and outcome. Fertil Steril 74:166-8, 2000. Full text
58. Itskovitz-Eldor J, Kol S Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: Short communication. Hum Reprod 15:1965-1968, 2000. Full text
59. Kol S, Itskovitz-Eldor J. Severe OHSS: yes, there is a strategy to prevent it! Hum Reprod. 15:2266-7, 2000. Full text
60. Kol S, Should we explore OHSS full clinical scope?… Hum Reprod. 16:595-6, 2001. Full text
61. Kol S, Kehat I, Adashi EY. Ovarian interleukin-1-induced gene expression: privileged genes threshold theory. Med Hypotheses. 58:6-8, 2002. Full text
62. Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J. Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertil Steril 79:1123-8, 2003. Full text
63. Kol S. Vascular endothelial growth factor – mediator of PHSS? Fertil Steril 79:1466, 2003.Full text
64. Kol S. Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent! Hum Reprod.18:1557-8. 2003. Full text
65. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 81:1-5, 2004. Full text
66. Kol S, Muchtar M. Recombinant gonadotrophin-based, ovarian hyperstimulation syndrome-free stimulation of the high responder: suggested protocol for further reseach. Reproductive BioMedicine Online 10:575-577, 2005. Full text
67. Kol S. To add or not to add LH: consideration of LH concentration changes in individual patients. Reproductive BioMedicine Online 11:664-666, 2005. Full text
68. Kol S, Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy? Journal of Assisted Reproduction and Genetics 25:63-66, 2008. Full text
69. Kol S, Homburg R. Change, change, change: hormonal actions depend on changes in blood levels. Human Reproducion 23:1004-6, 2008. Full text
70. Kol S, Dor J. Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation. Reproductive BioMedicine Online 19:59-60, 2009 Full text
71. Kol S, Humaidan P. LH (as hCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango. Reproductive BioMedicine Online 21:590-592, 2010 Full text
72. Kol S, Itskovitz-Eldor J. Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome–a 20-year experience. Semin reorod Med 28:500-505, 2010 Full text
73. Humaidan P, Kol S and Papanikolaou EG, on behalf of the ‘The Copenhagen GnRH Agonist Triggering Workshop Group’. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Human eproduction Update 2011;17:510-524 Full text
74. Kol S, Humaidan P, Itskovitz-Eldor J. GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study. Hum. Reprod. 26:2874-77, 2011Full text
75. E.G Papanikolaou, P.Humaidan, N. Polyzos, S Kalantaridou, Kol S, C. Benadiva, H.Tournaye, B. Tarlatzis. New algorithm for OHSS prevention. Reproductive Biology and Endocrinology 2011, 9:14, 2011 Full text
76. P. Humaidan, Kol S, L. Engmann, C. Benadiva, E.G. Papanikolaou, and C. Yding Andersen, on behalf of the Copenhagen GnRH Agonist Triggering Workshop Group. Should Cochrane reviews be performed during the development of new concepts? Hum. Reprod. 27:6-8, 2012. Full text
77. Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov-Kochman R. Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Hum. Reprod. 27:753-9, 2012 Full text
78. Kol S, Homburg R, Alsbjerg B, Humaidan P. The gonadotropin-releasing hormone antagonist protocol – the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation. ACTA Obstetrica et Gynecologica Scandinavica 91:643-7, 2012 Full text
79. Sella T, Segal Y, Goren I, Chodick G, Shalev V, Homburg R, Bachar R, Kol S. In-Vitro fertilization cycles and outcomes in Maccabi Healthcare Services in Israel 2007-2010. Harefuah 152:11-14, 2013. Full text See also See also
80. Kol S, Humaidan P. GnRH agonist triggering: recent developments. Reproductive BioMedicine Online 26: 226– 230, 2013. Full text
81. Mousavi Fatemi H, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, García-Velasco JA. Severe ovarian hyperstimulation after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze all" approach in GnRH antagonist protocol. Fertil Steril. 101:1008-11, 2014. Full text
82. Kol S, Tannus S, Lightman A, Itskovitz J. Assisted reproductive technology in the presence of chronic viral disease. Harefuah 153:155-158, 2014. Full text
83. Levron J, Zinchenko V, Kol S, Direnfeld M, Bider D. The use of portable CO2 incubator for cross-border shipping of embryos in an international egg donation program. Gynecol Endocrinol. 30:755-7, 2014. Full text
84. Kol S. Individualized Treatment from Theory to Practice: The Private Case of Adding LH during GnRH Antagonist-based Stimulation Protocol. Clinical Medicine Insights: Reproductive Health 8:59–64, 2014. Full text
85. Kol S, Humaidan P, Alsbjerg B, Engmann L, Benadiva C, García-Velasco JA, Fatemi H, Andersen CY. The updated Cochrane review 2014 on GnRH agonist trigger: repeating the same errors. Reproductive BioMedicine Online 30: 563– 565, 2015. Full text
86. Segal L, Breyzman T, Kol S. Luteal phase support post IVF: individualized early stop. Reproductive BioMedicine Online 31: 633–637, 2015. Full text
87. Kol S, Breyzman T, Segal L, Humaidan P. 'Luteal coasting' after GnRH agonist trigger – individualized, HCG-based, progesterone-free luteal support in 'high responders': a case series. Reprod Biomed Online. 31:747-751, 2015. Full text
88. Kol S, Breyzman T. GnRH agonist trigger does not always cause luteolysis: a case report. Reprod Biomed Online. 32:132-134, 2016. Full text
89. Tannus S, Burke YZ, Kol S. Treatment strategies for the infertile polycystic ovary syndrome patient. Womens Health (Lond Engl). 11:901-12, 2015.
90. Kol S, Bergovoy Yellin L, Segal Y and Porath A. In Vitro fertilization (IVF) treatments in Maccabi Healthcare Services 2007-2014. Israel Journal of Health Policy Research 5:14, 2016. DOI: 10.1186/s13584-016-0072-9. Full text
91. Hershkop E, Segal L, Fainaru O, Kol S. ‘Model’ versus ‘everyday’ patients: can randomized controlled trial data really be applied to the clinic?. Reprod Biomed Online. 34:274-279, 2017. Full text
92. Human Reproduction top 10% reviewers certificate, 30.3.2017 Certificate
93. Fainaru O, Kol S. How Many Embryos Should Be Transferred? The Relevance of Parity and Obstetric History. Isr Med Assoc J. 18:364, 2016. Full text
94. Segal L, Fainaru O, Kol S. Anovulatory Patients Demonstrate a Sharp Decline in LH Levels upon GnRH Antagonist Administration during IVF Cycles. Rambam Maimonides Medical Journal 8:21, 2017. Full text
95. Kol S, Fainaru O. GnRH Agonist Triggering of Ovulation Replacing hCG: A 30-Year-Old
Revolution in IVF Practice Led by Rambam Health Care Campus. Rambam Maimonides Medical Journal 8:23, 2017. Full text
96. Tannus S, Burke Y, McCartney CR, Kol S. GnRH-agonist triggering for final oocyte maturation in GnRH-antagonist IVF cycles induces decreased LH pulse rate and amplitude in early luteal phase: a possible luteolysis mechanism. Gynecol Endocrinol. 25:1-5, 2017. Full text
97. Vanetik S, Segal L, Breizman T, Kol S. Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger – a proof of concept study. Gynecol Endocrinol. 2018;34:132-135. Full text
98. Kol S, Gal M. False positive blood hCG test following Corifollitropin alfa injection. Hum Reprod. 2017 Oct 31:3. Full text
99. Eshet S, Milner E, Segal L, Monzer A, Kol S. IN VITRO FERTILIZATION (IVF) TREATMENT FOR VIRAL DISEASES CARRIERS: SUMMARY OF TREATMENT OUTCOME OF HIV-POSITIVE PATIENTS. Harefuah. 2017 Oct;156:670. Full text
100. Lawrenz B, Humaidan P, Kol S, Fatemi HM. GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient? Reprod Biomed Online. 2017 Oct 14 . Full text
101. Kol S. A Rationale for Timing of Luteal Support Post Gonadotropin-Releasing Hormone Agonist Trigger. Gynecol Obstet Invest. 2018 Jul 13:1-5. doi: 10.1159/000491088 . Full text
102. Kol S. Ultra-Orthodox Jews and infertility diagnosis and treatment. Andrology. 2018;6:662-664. doi: 10.1111/andr.12533 . Full text
103. Shuchat S, Park S, Kol S, Yossifon G. Distinct and independent dielectrophoretic behaviour of the head and tail of sperm and its potential for the safe sorting and isolation of rare spermatozoa. Electrophoresis. 2019;40:1606-1614.
104. Kol S, Fainaru O. Inadvertent use of depot GnRH agonist trigger and its effect on the luteal phase. A case report. Reproductive Medicine International 2018;1:1-2. Full text
105. Vanetik S, Beck-Fruchter R, Segal L, Kol S. The Importance of Mid-Follicular Phase Luteinizing Hormone Rise in GnRH Antagonist-Based Ovarian Stimulation for IVF. Gynecol Obstet Invest. 2020;85:184-188. Full text
106. Kol S. LH Supplementation in Ovarian Stimulation for IVF: The Individual, LH Deficient, Patient Perspective. Gynecol Obstet Invest. 2020;85:307-311. Full text
107. Kol S, Segal L. GnRH agonist triggering followed by 1500 IU of HCG 48 h after oocyte retrieval for luteal phase support. Reproductive Biomedicine Online. 2020;41:854-858. Full text
108. Kol S, Humaidan P. IVF and the exogenous progesterone-free luteal phase. Curr Opin Obstet Gynecol. 2020 Dec 24 Full text
109. Humaidan P, Kol S. Suboptimal response to GnRH agonist trigger: causes and practical management. Curr Opin Obstet Gynecol. 2021 Feb 23 Full text
110. E. Bosch, C. Alviggi, M. Lispi, A. Conforti, A.C. Hanyaloglu, D. Chuderland, M. Simoni, N. Raine-Fenning, P. Cre´ pieux, S. Kol, V. Rochira, T. D’Hooghe, and P. Humaidan. Reduced FSH and LH action: implications for medically assisted reproduction. Human Reproduction, 2021 Full text
111. P. Humaidan, B. Alsbjerg, H.O. Elbaek, B.B. Povlsen, R.J. Laursen, M.B. Jensen, A.T. Mikkelsen L.H. Thomsen, S. Kol, T. Haahr. The exogenous progesterone-free luteal phase: two pilot randomized controlled trials in IVF patients. Reprod Biomed Online, Published: March 17, 2021 Full text
112. S. Kol. Time, time time: see what governs the luteal phase endocrinology. Gynecological Endocrinology, published: June 4, 2021 Full text
113. S. Kol P. Humaidan. Luteinizing Hormone and Ovarian Stimulation for In-Vitro Fertilization: Do Science and Business Always Agree? Science Repository, published: August 22, 2022 Full text
114. J. Castillo, S. Kol. Time-sensitive assessment of luteal phase progesterone after hCG ovulation triggering: Another brick off the wall? RBMO VOLUME 47, ISSUE 5, 2023, 103324. Full text
115. Castillo J, Quaas AM, Kol S. LH supplementation in IVF: human nature, politics, and elephants in the room. J Assist Reprod Genet. 2024 Jan 22. Full text
116. Castillo J, Kol S. Ideal frozen embryo transfer regime. Curr Opin Obstet Gynecol. 2024 Feb 1. Full text
117. Orvieto N, Segal Y, Kol S. In Vitro fertilization (IVF) treatments in Maccabi Healthcare Services 2015-2020. Harefua March 2024 (Hebrew). Full text
118. Kol S, Castillo J, Trolice MP, Quaas AM. Monitoring of controlled ovarian stimulation in IVF. J Assist Reprod Genet.2024, 41:1715–1717 Full text
